Return to home page
Searching: Muskingum library catalog
We are currently experiencing delivery delays for items requested from other institutions while transitioning to a new statewide delivery service. Please contact your library with questions or advice about alternative resources. Thank you for your patience!
  Previous Record Previous Item Next Item Next Record
  Reviews, Summaries, etc...
EBOOK
Author Mauskopf, Josephine,
Title Budget-impact analysis of health care interventions : a practical guide / Josephine Mauskopf, Stephanie R. Earnshaw, Anita Brogan, Sorrel Wolowacz, Thor-Henrik Brodtkorb.
Imprint Cham, Switzerland : ADIS, [2017]

LOCATION CALL # STATUS MESSAGE
 OHIOLINK SPRINGER EBOOKS    ONLINE  
View online
LOCATION CALL # STATUS MESSAGE
 OHIOLINK SPRINGER EBOOKS    ONLINE  
View online
Author Mauskopf, Josephine,
Subject Medical care -- Cost effectiveness.
Medical economics.
Health Care Costs.
Cost-Benefit Analysis.
Budgets.
Alt Name Earnshaw, Stephanie R.,
Brogan, Anita Jean,
Wolowacz, Sorrel,
Brodtkorb, Thor-Henrik,
Description 1 online resource (234 pages)
Note Print version record.
Contents Author Contributions; Foreword; Preface; Abbreviations; Contents; Chapter 1: Introduction to Budget-Impact Analysis; 1.1 What Is Budget-Impact Analysis?; 1.2 Budget-Impact Analyses Compared with Cost-Effectiveness Analyses; 1.3 Uses of Budget-Impact Analyses; 1.4 Guidelines for Budget-Impact Analyses; 1.5 Overview of Chapters in This Book; Exercises; References; Chapter 2: Determining the Analytic Framework; 2.1 Eligible Population in Jurisdiction; 2.1.1 Impact of Positioning of the New Drug Within the Current Treatment Pathway on Eligible Population Size.
2.1.2 Impact of Regulatory Approval on Eligible Population Size2.1.3 Impact of Reimbursement Decisions on Eligible Population Size; 2.1.4 Impact of New Drug Attributes on Initial Population Size; 2.1.5 Impact of New Drug Attributes on Population Size Over Model Time Horizon; 2.2 Budget Holder Time Horizon; 2.3 Potential Use of the New Drug Within the Treatment Mix; 2.4 Budget Holder Cost Perspective; 2.4.1 Service Delivery Cost Versus Reimbursement Rate; 2.4.2 Fixed Versus Variable Costs; 2.4.3 Cost Categories of Interest; 2.5 Compilation of Analytic Framework; Exercises; References.
Chapter 3: Estimating the Diagnosed, Treated, and Eligible Population3.1 Incident and Prevalent Populations; 3.2 Estimating the Eligible Population Size; 3.3 Data for Identifying the Eligible Population; 3.4 Estimating Population Size by Subgroup; 3.5 Changing Size of the Eligible Population Over the Analysis Time Horizon; 3.5.1 Changing Population Size Regardless of Introduction of the New Drug; 3.5.2 Changing Population Size and Condition Severity Mix due to the Introduction of the New Drug; 3.6 Including Catch-Up Effects for the Prevalent Population.
3.7 Which Eligible Population Should We Include in the Budget-Impact Analysis?Exercises; References; Chapter 4: Estimating the Treatment Mix; 4.1 Treatment Shares Without the New Drug in the Treatment Mix; 4.2 Treatment Shares with the New Drug in the Treatment Mix; 4.3 Which Treatment Shares Should We Include in the Budget-Impact Analysis?; Exercises; Reference; Chapter 5: Estimating Treatment-Related Costs; 5.1 Costs for Drug Acquisition; 5.1.1 Co-payments and Coinsurance; 5.1.2 Dispensing Fees; 5.1.3 Dose Levels; 5.1.4 Duration of Treatment; 5.2 Costs for Administering the Drug.
5.3 Costs for Diagnostic Tests to Determine Eligibility for the Drug5.4 Costs for Monitoring the Drug for Safety and Efficacy; 5.5 Costs for Treating Side Effects Associated with the Drug; 5.6 Accounting for Differing Treatment Costs in the First and Subsequent Treatment Years; 5.7 Accounting for Other Treatment Costs; 5.8 Estimating Resource Use Changes with the New Drug; Exercises; References; Chapter 6: Estimating Condition-Related Costs; 6.1 Why the New Drug Might Change Condition-Related Costs; 6.2 Estimating Changes in Condition-Related Costs for Incident Populations.
Note 6.2.1 Acute Conditions or Chronic Conditions Where Changes Occur Almost Immediately.
Summary The first of its kind for budget-impact analysis, this comprehensive guide provides clear and concise instructions for evaluating the impact that new pharmaceuticals will have on the budget for a specific jurisdiction. The book demonstrates how to create a budget-impact analysis using a simple six-step process that is consistent with current guidelines for these analyses. Examples and exercises for each chapter afford an opportunity to practice the six-step process in practical applications. The book progresses from a framework for budget impact analyses to an in-depth review of components and how to develop and present these in software applications and reports. Critical considerations such as uncertainty analysis and validation, and considerations for alternate interventions, such as vaccines and diagnostics, are also covered. This book is a "must have" for the builder and budget holder, with builders benefiting from instructions to identify and estimate all necessary variables and budget holders receiving a guide to what should be included in the analyses they assess.
ISBN 9783319504827 (electronic bk.)
3319504827 (electronic bk.)
9783319504803
3319504800
ISBN/ISSN 10.1007/978-3-319-50482-7
OCLC # 1000451702
Additional Format Print version: Mauskopf, Josephine. Budget-Impact Analysis of Health Care Interventions : A Practical Guide. Cham : Springer International Publishing, 2017 9783319504803 (OCoLC)962125865.



If you experience difficulty accessing or navigating this content, please contact the OPAL Support Team